"Receiving the NIH Director's New Innovator Award is a tremendous privilege, and I view it as an opportunity to serve the American public who make this research possible through their investment in science. It is not just recognition of our lab's work, but also a commitment to pursuing bold, high-risk ideas that can truly change the lives of children, halting brain damage that would otherwise result in a lifetime of disability,"
"Today, personalized genetic treatments take years to develop, time that these children simply cannot afford as every seizure presents the risk of irreversible brain damage. Our goal is to create faster, broadly effective RNA-based therapies that can stabilize brain activity and buy critical time while precision treatments are designed,"
Richard Smith, PhD, assistant professor of Pharmacology and of Pediatrics, received the NIH Director's New Innovator Award to pursue high-risk, innovative biomedical research. The research aims to develop novel therapeutics that target the brain in children with severe epilepsy sooner and more effectively than current personalized treatments. The award will fund identification of a broader set of signaling pathways implicated in excitatory/inhibitory neuronal balance during early brain development using high-throughput biology, advanced tissue modeling with cerebral organoids, and RNA-based technologies. The goal is to create faster, broadly effective RNA-based therapies that stabilize brain activity and buy critical time while precision treatments are developed.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]